Streetbeat News

Stock Prices

CRSP

CRISPR Therapeutics (NASDAQ:CRSP) has delivered an average annual return of 18.46% over the past 5 years, outperforming the market by 5.73% annually. A $1000 investment in CRSP 5 years ago would be worth $2,129.63 today. The company's market capitalization stands at $6.94 billion.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 7:00 pm

AME

AMETEK (NYSE:AME) has delivered an average annual return of 17.58% over the past 5 years, outperforming the market by 4.85%. A $1000 investment in AME 5 years ago would now be worth $2,229.66. The company's current market capitalization stands at $41.24 billion.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 7:00 pm

SOLUSD

Solana (CRYPTO: SOL) has seen a 3.3% decrease in price over the last 24 hours, continuing a negative trend of a 7.0% loss over the past week. Despite the price drop, trading volume for SOL has increased by 8.0%, while its circulating supply decreased by 0.14%, leading to a current market cap ranking of #5 at $44.71 billion.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 7:00 pm

MODV

ModivCare Inc (NASDAQ:MODV) reported Q4 2023 revenue of $702.8 million, a 7.5% increase year-over-year, surpassing consensus estimates. Despite revenue growth, driven by an increase in non-emergency medical transportation trips and personal care services hours, the company's adjusted EPS fell to $1.29 from $2.11 a year ago, slightly above consensus. The decrease in membership due to Medicaid redetermination and margin pressure in the NEMT segment were noted as challenges. Deutsche Bank and Jefferies downgraded MODV, significantly lowering their price targets. ModivCare forecasts lower than expected revenues for Q1 2024 and the full year, contributing to a 40.6% drop in its stock price.

Portfolio Pulse from Vandana Singh

February 23, 2024 | 6:54 pm

MOVE

Movano Inc. shares surged following the announcement that the company has received a notice of allowance for its U.S. patent application, indicating a significant step forward in its intellectual property portfolio.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 6:51 pm

ENVB

Enveric Biosciences' stock is trading higher following the announcement that the company has agreed to sell its cancer-targeting cannabinoid-related intellectual property.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 6:40 pm

AAPL

AMZN

GOOG

META

MSFT

NVDA

QQQ

SPY

TSLA

The stock market reached a new high, driven by a renewed AI frenzy, particularly after NVIDIA Corp's earnings announcement, which saw its stock value surge by a record $277B in one day. This AI enthusiasm has overshadowed concerns such as high interest rates and overestimated earnings outside of AI. Early trade money flows show positive trends for Meta Platforms, Microsoft, and NVIDIA, neutral for Apple and Alphabet, and negative for Amazon and Tesla. Mixed money flows are observed in SPDR S&P 500 ETF Trust and Invesco QQQ Trust. The article also notes the impact on gold, oil, and Bitcoin markets, with specific ETFs mentioned for each.

Portfolio Pulse from The Arora Report

February 23, 2024 | 6:36 pm

AMZN

FFND

RIVN

Rivian Automotive, Inc. (RIVN) stock dropped over 8% in a day, adding to a 25.60% loss due to poor 2024 production guidance. Tesla investor Gary Black supports Rivian as a potential number two in the EV market, citing its high-quality product and brand recognition. Black also sees Rivian's cash position as strong and hints at a possible acquisition by Amazon (AMZN). Rivian's upcoming R2 launch event is seen as a key catalyst. Future Fund Active ETF (FFND) holds shares in both Tesla and Rivian.

Portfolio Pulse from Shanthi Rexaline

February 23, 2024 | 6:35 pm

NTLA

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) from Buy to Neutral and set a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 6:34 pm

FANG

Diamondback Energy (NYSE:FANG) has seen a 7.82% decrease in its short percent of float, now at 3.42% with 5.36 million shares sold short. This indicates a more bullish sentiment among investors compared to its peers, where the average short interest as a percentage of float is 6.34%. The reduction in short interest suggests fewer traders are betting against the stock, potentially signaling a positive outlook for FANG in the short term.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 6:30 pm